Solithromycin monotherapy for treatment of community-acquired bacterial pneumonia: A meta-analysis of randomised controlled trials

International Journal of Clinical Practice
Junlin WenXiaoping Wang

Abstract

Solithromycin is a new monotherapy option for community-acquired bacterial pneumonia (CABP) patients. However, the efficacy and safety of solithromycin monotherapy for the treatment of CABP remains controversial. The aim of this meta-analysis was to evaluate the role that solithromycin played in the treatment of CABP. We systematically retrieved randomised controlled trials (RCTs) compared solithromycin with other antibiotics in the treatment of CABP, which were published on PubMed, ScienceDirect, Cochrane libary and the Clinical Trials.gov before July 2018. Ultimately, a meta-analysis of all RCTs eligible for inclusion criteria was performed. Three RCTs, comprising 1855 patients, were included in the meta-analysis. There were no statistically significant differences between patients given solithromycin and those given other antibiotics with regard to early clinical response (ECR) [1855 patients, odds ratio (OR) = 1.00, 95% confidence interval (CI) 0.80 to 1.24, P = 0.99] and clinical success rates at short-term follow-up (SFU) (1855 patients, OR = 0.78, 95% CI 0.60 to 1.01, P = 0.06) in the intention-to-treat (ITT) population, as were the ECR (787 patients, OR = 0.90, 95% CI 0.64 to 1.27, P = 0.55) and clinical success rates a...Continue Reading

References

Jan 1, 1996·International Journal of Technology Assessment in Health Care·D MoherP Tugwell
Oct 26, 2000·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·M A KelleyM S Cohen
Sep 29, 2001·Journal of Clinical Epidemiology·J A Sterne, M Egger
Feb 22, 2002·The New England Journal of Medicine·Daniel M MusherKurt L Krause
Aug 13, 2002·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·John R LonksAntone A Medeiros
Jun 21, 2005·Emerging Infectious Diseases·Keith P Klugman, John R Lonks
Oct 6, 2005·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Jacques PépinLuc Lanthier
Feb 6, 2007·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Lionel A MandellUNKNOWN American Thoracic Society
Dec 17, 2008·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·Allen D BrinkerLeonard B Seeff
Mar 6, 2010·Postgraduate Medicine·Thomas M File, Thomas J Marrie
Sep 22, 2010·Antimicrobial Agents and Chemotherapy·Beatriz Llano-SoteloAlexander S Mankin
Nov 16, 2010·International Journal of Antimicrobial Agents·Shannon D PutnamMariana Castanheira
Jan 30, 2013·The Journal of Pharmacology and Experimental Therapeutics·Yoshiki KobayashiKazuhiro Ito
Apr 16, 2013·Diagnostic Microbiology and Infectious Disease·Jacob P BruinJohan W Mouton
May 9, 2013·Expert Opinion on Drug Safety·Ralf Stahlmann, Hartmut M Lode
Nov 28, 2013·Antimicrobial Agents and Chemotherapy·Julia MallegolCyril Guyard
Dec 7, 2013·European Journal of Clinical Microbiology & Infectious Diseases : Official Publication of the European Society of Clinical Microbiology·A TóthM Füzi
Feb 7, 2014·The New England Journal of Medicine·Richard G Wunderink, Grant W Waterer
Oct 23, 2014·The New England Journal of Medicine·Daniel M Musher, Anna R Thorner
Jul 15, 2015·The New England Journal of Medicine·Seema JainUNKNOWN CDC EPIC Study Team
Feb 6, 2016·Expert Review of Anti-infective Therapy·Françoise Van Bambeke, Paul M Tulkens
Apr 6, 2016·Antimicrobial Agents and Chemotherapy·David J FarrellRonald N Jones
Nov 1, 2016·Expert Review of Respiratory Medicine·Diego ViasusJordi Carratalà

❮ Previous
Next ❯

Citations

Jul 11, 2019·Open Biology·Anne WitzkyMichael Ibba
Oct 18, 2019·Expert Opinion on Pharmacotherapy·Matteo BassettiMaddalena Peghin
Dec 4, 2020·Journal of Infection and Chemotherapy : Official Journal of the Japan Society of Chemotherapy·Hideo KatoHiroshige Mikamo
Jun 3, 2021·International Journal of Molecular Sciences·Rya EroYong-Gui Gao
Aug 28, 2021·Antibiotics·Firzan NainuJesus Simal-Gandara
Nov 6, 2021·Frontiers in Pharmacology·Man WuYonggang Zhang

❮ Previous
Next ❯

Related Concepts

Related Feeds

Bacterial Pneumonia (ASM)

Bacterial pneumonia is a prevalent and costly infection that is a significant cause of morbidity and mortality in patients of all ages. Here is the latest research.

Bacterial Pneumonia

Bacterial pneumonia is a prevalent and costly infection that is a significant cause of morbidity and mortality in patients of all ages. Here is the latest research.